C
VKTX icon

Covestor’s Viking Therapeutics VKTX Stock Holding History

Covestor’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
253
+17
+7% +$549 0.01% 1630
2026
Q1 		$8K Sell
236
-188
-44% -$6.04K 0.01% 1623
2025
Q4 		$15K Hold
424
– – 0.01% 1412
2025
Q3 		$11K Sell
424
-1
-0.2% -$30 0.01% 1575
2025
Q2 		$11K Sell
425
-829
-66% -$21.8K 0.01% 1567
2025
Q1 		$30K Buy
1,254
+1,094
+684% +$34.6K 0.02% 1048
2024
Q4 		$6K Buy
160
+2
+1% +$114 ﹤0.01% 1703
2024
Q3 		$10K Buy
158
+1
+0.6% +$59 0.01% 1590
2024
Q2 		$8K Buy
157
+153
+3,825% +$10K 0.01% 1695
2024
Q1 		$0 Sell
4
-4
-50% -$178 ﹤0.01% 2790
2023
Q4 		$0 Sell
8
-1
-11% -$13 ﹤0.01% 2766
2023
Q3 		$0 Buy
+9
New +$129 ﹤0.01% 2761

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Covestor's VKTX Position: Q2 2026 in Review

Covestor increased its Viking Therapeutics (VKTX) stake by 7.2% in Q2 2026, buying an estimated $549 and bringing the position to 253 shares worth $10K. The position accounts for 0.01% of the portfolio, ranked #1630.

Covestor first reported a position in VKTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $30K in Q1 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Covestor held 253 shares of Viking Therapeutics worth $10K as of Q2 2026.
  • Covestor bought 17 Viking Therapeutics shares in Q2 2026, an estimated $549.
  • Viking Therapeutics made up 0.01% of Covestor's portfolio in Q2 2026, its #1630 holding.
  • Covestor first reported a position in Viking Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Covestor's Viking Therapeutics position peaked at $30K in Q1 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.